Objectives: This study aims to evaluate our injection laryngoplasty experience in patients with unilateral vocal fold paralysis.
Patients with unilateral vocal fold paralysis (UVFP) often suffer reduced quality of life because of voice and swallowing difficulties. Unless there is severe swallowing impairment, treatment focuses on improving voice quality, thereby improving quality of life. [1] Management options include observation, voice therapy, and surgery. Various techniques have been proposed for managing vocal fold paralysis. These techniques include laryngeal framework surgery, reinnervation surgery, and injection laryngoplasty (IL). Injection laryngoplasty has several potential advantages when compared with other procedures. These advantages include avoidance of an open surgical procedure, lower procedural cost and morbidity, as well as the potential application of these techniques to the outpatient clinical setting with minimal anesthetic requirements. [2] Injection laryngoplasty has traditionally been performed under general anesthesia in the operating room. Recently there has been a resurgence of interest in awake IL, a technique first reported in 1985 by Ward et al. [3] Awake IL has been demonstrated to be a safe and clinically comparable alternative to IL under general anesthesia. The ideal vocal fold injection material should be biologically inert, "available off the shelf" (no preparation required for use), present no risk of infectious disease transmission, be a good rheologic match with injection site biologic tissue, and have the ability to be used with a fine-gauge injection needle. [4] In its natural state in the body, calcium hydroxyapatite (CaHA) is a major component of the mineral constituent of both bone and teeth. Calcium hydroxyapatite has been used as a biomedical implant in a variety of applications in the body, including dental, orthopedic, and head and neck bony reconstructions. In these locations, CaHA has proven to be a stable implant material with minimal inflammatory response and no evidence of toxicity. Recently, CaHA has been formulated for vocal fold augmentation. [4] The purpose of this study is to evaluate the safety and efficacy of CaHA for vocal fold augmentation in UVFP and to compare awake IL to more traditional IL under general anesthesia by using the Voice Handicap Index (VHI) scoring system and to review our experience with it. 
PATIENTS AND METHODS

RESULTS
The leading etiologic factor was thyroidectomy. Thirteen patients (19.1%) had thyroidectomy, 10 (14.7%) idiopathic UFVP; eight patients (11.7%) had lung, two patients (2.9%) esophageal, and two patients (2.9%) thyroid carcinoma; seven patients (10.2%) had intubation history; three patients (4.4%) had intracranial surgery; three patients (4.4%) had trauma history; four patients (5.8%) had thoracic interventions, eight patients (11.7%) had glomus tumor/resection, two patients (2.9%) had undergone a carotid endarterectomy, one patient (1.4%) a cervical fusion, and five patients (7.3%) had other reasons.
Twenty-four patients (35.2%) underwent awake IL (Figure 1 ), 41 patients (60.2%) underwent asleep IL ( Figure 2 ) and three patients underwent multiple injections both awake and asleep. There were five complications and all were related with awake IL. The perioperative complications were minimal bleeding in one patient and difficulty tolerating the procedure because of gagging reflex in two patients. The postoperative complication was vocal fold stiffness in two patients. Eleven patients (16.1%) underwent speech therapy before IL and nine patients (13.2%) had speech therapy following IL. Six patients (8.8%) underwent thyroplasty after IL. The main reason for thyroplasty was short-lived benefit from the injection laryngoplasty. At this point reinjection and thyroplasty was discussed with patients and these patients chose to undergo thyroplasty with implant. Average follow-up period was 36 weeks (range 0-340.4 weeks).
The subgroup of 29 patients who at least had a post-injection VHI score was analyzed further. Sixteen patients (55%) were female; the mean patient age was 60 years old (range 27-86 years old). Seventeen patients underwent direct microlaryngoscopy with suspension, 12 patients underwent in-office percutaneous injections (through the cricothyroid membrane). Postinjection VHI scores were between 4 to 87 (mean, 36.7). Majority of the patients whose VHI scores were more than 40 were cancer patients undergoing active treatment. Pre-and post-injection VHI data was available for 20 patients and half of them were percutaneously injected. Average VHI in the 20 patients improved 27.9 points. While the average VHI in the patients percutaneously injected improved 35.1 points, average VHI in the direct laryngoscopy group improved 20.7 points. (T-test, p=0.29). There was worsening of one patient's post-injection VHI score; this patient had lung carcinoma and deterioration of his general health.
DISCUSSION
Enhancing quality of life by creating a more effective and understandable voice is the primary purpose of phonosurgical vocal fold injection. [5] Injection laryngoplasty for the treatment of UVFP has been subject to dramatic changes in recent years. Advancement of both injection techniques and biocompatible materials have propelled the field of laryngology to a new level. [6] Injection materials can be categorized by the origin of material as xenograft, homograft, autograft, and synthetic materials. Calcium hydroxyapatite is one of the synthetic materials. [2] Only a moderate amount of information is available about CaHA as a vocal fold augmentation material. [4] It is a calcium phosphorus compound that is a basic component of bone and teeth. It is provided in the form of microspheres with gel carrier so that it can be injected through a fine needle. In an animal study, the histologic analysis showed no resorption of microspheres up to a 12-month observation period, but some reduction in medialization was noted because of the resorption of the gel carrier. Therefore, slight over-injection and/or repeated injection may be necessary. [2] Chhetri et al. [7] looked at the histology, host tolerance, and mucosal wave vibration in canine larynges up to 12 months after CaHA vocal fold injection. The histologic results throughout the study showed no significant immunologic response, and no CaHA was found in the lymph nodes of the neck or other parts of the body. No evidence of stiffness in the in vivo canine stroboscopy model was found during the mucosal wave vibrational assessment. On the other hand, Tanna et al. [8] reported on a case of intense inflammatory response in a patient after CaHA vocal fold augmentation. The CaHA material was partially removed four weeks after injection, and histologic examination revealed a "chronic inflammatory infiltrate and numerous foreign body giant cells''. Rosen et al. [4] prospectively evaluated the effectiveness of CaHA up to 12-month time point in 63 patients. At 12 months, 81% of patients subjectively reported at least moderate improvement in their voice. Belafsky and Postma [9] reported a 100% improvement on a self-administered disease-specific outcome measure in a total of 39 vocal fold injections in 23 individuals who were injected with CaHA. Carroll and Rosen [10] later reported the average length of benefit as 27.2 months with a range of 8 to 60 months in 20 patients with 22 separate injections. There were three complications out of 108 injections: one superficial injection and two infraglottic submucosal collections of CaHA. Although not life threatening, these complications did require surgical removal. A more recent paper by Gillespie et al. [11] describes a 21% complication rate with CaHA, and the majority of the complications were due to superficial injection of CaHA. Our complication rate was 7.3% and all were minor complications, this is in concurrence with the literature indicating CaHA as a safe and effective alternative for vocal fold augmentation. We should note that despite having no major complications noted in UFVP patients, we encountered two older patients who underwent bilateral vocal fold injections due to presbylarynx, who had shifting of the material to the vocal fold free edge. Both patients had significant vocal fold atrophy and both injections were performed under general anesthesia. In both cases the material had to be removed with microlaryngoscopy and incision. One of these patients received speech therapy following this. Special attention needs to be paid in this patient population where the structures are significantly altered due to atrophy.
Recently available flexible laryngoscopic imaging technologies (distal chip camera) and new injection materials, which are able to flow through a fine-gauge needle, have made performing IL in the office a viable alternative to traditional, operating room-based IL. [12] Sulica et al. [13] reported that the number of in-office injections increased from 11 to 43% between 2003 and 2008. Two factors have been fundamental in permitting this return to the clinic setting. The first is the availability of a variety of injectable materials, most of them recently adapted or introduced for laryngeal use. The second advance is the improved quality of visualization of the larynx in the awake patient. In their study, decisions regarding method of injection (awake vs. asleep) were usually based on physician and/or patient preference and several medical comorbidities led surgeons to avoid a general anesthetic in seven cases. [13] In our series the average number of comorbidities was 2 in the awake group and 1.7 in the asleep group. While patient preference does play a role in the selection of the technique, the most important factor determining the mode of injection in this series has been the general health of the patient. Patients undergoing therapy for malignancies such as esophageal or lung carcinoma have been injected in the office in order not to introduce risks of general anesthesia. Also, the awake injection group was slightly older (62.5 years old vs. 57.5 in the asleep group, p=0.07). On the other hand, professional voice users were generally injected in the operating room, to achieve a more precise injection.
Mathison et al. [3] have demonstrated equivalent outcomes in Voice Related Quality of Life (VRQOL) measures in patients who undergo awake versus asleep IL in a retrospective casecontrol review of 141 patients with 166 injections. In this study, 105 IL were performed under general anesthesia. Average VRQOL in the awake patient improved by 25.05 points whereas average VRQOL in the asleep patient improved 20.81 points. Bove et al. [12] analyzed reimbursement in awake and asleep injection laryngoplasties in a group of 197 patients with a total of 211 injections. Awake IL was found to be less expensive than traditional injection under direct vision and general anesthesia ($11,890 compared to $1,408 for in-office injections). [12] Mathison, however has noted increased complications with awake injection, including rapid absorption of the injected material, vasovagal reactions, inadvertent injection into the superficial lamina propria, and vocal fold hematoma. They used five different products--micronized dermis, hyaluronic acid, collagen, CaHA, and sodium carboxymethyl cellulose. [3] In this series of 68 patients, all complications were noted in office injections and they were all minor complications. Our experience does show that there is a steeper learning curve for in-office injections, but that is a reproducible procedure once mastered. We measured voice outcomes by selfassessed VHI scores. The voice handicap index is a widely used self-administered questionnaire that assesses the patients' perceived degree of handicap related to their voice. [14] Average VHI in the 20 patients (awake and asleep totally) improved 27.9 points in a period of 1.8 to 81.8 weeks. Average VHI in the patients percutaneously injected improved 35.1 points, and average VHI in the asleep patients improved 20.7 points. There was no statistically significant relationship (p=0.29). Selecting appropriate patients for IL is critical to the success of such a technique. The ideal IL patient would present with a symptomatic complaint that they are motivated to improve upon. [2] 
Conclusions
This study supports injection laryngoplasty, both percutaneous and under direct laryngoscopy, with calcium hydroxyapatite as a safe and effective intervention for patients with VF paralysis.
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